Literature DB >> 23956427

A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling.

Feng Fang1, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei, John Varga.   

Abstract

Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN. Scleroderma patients with progressive skin fibrosis display an IFN-regulated gene signature, implicating TLR3 signaling in the disease. In this study, we show that TLR3 expression was detected on foreskin, adult skin, and lung fibroblasts, and TLR3 levels were significantly elevated in a subset of scleroderma skin biopsies. In explanted skin and lung fibroblasts, the synthetic TLR3 ligand polyinosinic-polycytidylic acid (poly(I:C)), a dsRNA analog, caused dose- and time-dependent stimulation of IFN-β production and generation of an IFN-response gene signature that was accompanied by substantial downregulation of collagen and α-smooth muscle actin gene expression. Furthermore, poly(I:C) abrogated TGF-β-induced fibrotic responses and blocked canonical Smad signaling via upregulation of inhibitory Smad7. Surprisingly, the inhibitory effects of poly(I:C) in fibroblasts were independent of TLR3 and were mediated by the cytosolic receptors retinoic acid-inducible gene 1 and melanoma differentiation-associated gene 5, and involved signaling via the IFN receptor. Taken together, these results demonstrate that induction of a fibroblast IFN response gene signature triggered by dsRNA is associated with potent TLR3-independent anti-fibrotic effects. The characteristic IFN response gene signature seen in scleroderma lesions might therefore signify a tissue-autonomous protective attempt to restrict fibroblast activation during injury.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23956427      PMCID: PMC3924580          DOI: 10.4049/jimmunol.1300376

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs.

Authors:  Anna Yarilina; Edward DiCarlo; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

2.  lumi: a pipeline for processing Illumina microarray.

Authors:  Pan Du; Warren A Kibbe; Simon M Lin
Journal:  Bioinformatics       Date:  2008-05-08       Impact factor: 6.937

3.  TLR3-mediated synthesis and release of eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA.

Authors:  Kyoko Niimi; Koichiro Asano; Yoshiki Shiraishi; Takeshi Nakajima; Misa Wakaki; Junko Kagyo; Takahisa Takihara; Yusuke Suzuki; Koichi Fukunaga; Tetsuya Shiomi; Tsuyoshi Oguma; Koichi Sayama; Kazuhiro Yamaguchi; Yukikazu Natori; Misako Matsumoto; Tsukasa Seya; Mutsuo Yamaya; Akitoshi Ishizaka
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

4.  A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.

Authors:  Michael R York; Taro Nagai; Alyson J Mangini; Raphaël Lemaire; Jean Maguire van Seventer; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2007-03

5.  Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma.

Authors:  Hangjun Duan; Jo Fleming; David K Pritchard; Lynn M Amon; Jun Xue; Heather A Arnett; Guang Chen; Patricia Breen; Jane H Buckner; Jerry A Molitor; Keith B Elkon; Stephen M Schwartz
Journal:  Arthritis Rheum       Date:  2008-05

Review 6.  Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis.

Authors:  John Varga; Boris Pasche
Journal:  Curr Opin Rheumatol       Date:  2008-11       Impact factor: 5.006

7.  Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems.

Authors:  Anna M Lundberg; Stefan K Drexler; Claudia Monaco; Lynn M Williams; Sandra M Sacre; Marc Feldmann; Brian M Foxwell
Journal:  Blood       Date:  2007-07-27       Impact factor: 22.113

8.  Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter.

Authors:  Feng Fang; Giovanni Antico; Jiamao Zheng; Charles V Clevenger
Journal:  BMC Biotechnol       Date:  2008-02-06       Impact factor: 2.563

9.  Model-based variance-stabilizing transformation for Illumina microarray data.

Authors:  Simon M Lin; Pan Du; Wolfgang Huber; Warren A Kibbe
Journal:  Nucleic Acids Res       Date:  2008-01-04       Impact factor: 16.971

10.  Molecular subsets in the gene expression signatures of scleroderma skin.

Authors:  Ausra Milano; Sarah A Pendergrass; Jennifer L Sargent; Lacy K George; Timothy H McCalmont; M Kari Connolly; Michael L Whitfield
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

View more
  19 in total

1.  Profibrotic Activation of Human Macrophages in Systemic Sclerosis.

Authors:  Rajan Bhandari; Michael S Ball; Viktor Martyanov; Dillon Popovich; Evelien Schaafsma; Saemi Han; Mohamed ElTanbouly; Nicole M Orzechowski; Mary Carns; Esperanza Arroyo; Kathleen Aren; Monique Hinchcliff; Michael L Whitfield; Patricia A Pioli
Journal:  Arthritis Rheumatol       Date:  2020-05-31       Impact factor: 10.995

2.  The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway.

Authors:  Lukasz Stawski; Grace Marden; Maria Trojanowska
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

Review 3.  Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.

Authors:  Swati Bhattacharyya; John Varga
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 4.  Toll-like receptors in mediating pathogenesis in systemic sclerosis.

Authors:  L Frasca; R Lande
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

5.  Estradiol-regulated innate antiviral responses of human endometrial stromal fibroblasts.

Authors:  Mickey V Patel; Zheng Shen; Richard M Rossoll; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2018-09-17       Impact factor: 3.886

Review 6.  Novel insights into the role of inflammasomes in autoimmune and metabolic rheumatic diseases.

Authors:  Kleopatra Deuteraiou; George Kitas; Alexandros Garyfallos; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2018-06-04       Impact factor: 2.631

7.  Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.

Authors:  A Paradowska-Gorycka; A Wajda; B Stypinska; E Walczuk; E Rzeszotarska; M Walczyk; E Haladyj; K Romanowska-Prochnicka; A Felis-Giemza; A Lewandowska; M Olesińska
Journal:  Clin Exp Immunol       Date:  2021-01-17       Impact factor: 5.732

8.  Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.

Authors:  Elena Raschi; Cecilia Beatrice Chighizola; Laura Cesana; Daniela Privitera; Francesca Ingegnoli; Claudio Mastaglio; Pier Luigi Meroni; Maria Orietta Borghi
Journal:  Arthritis Res Ther       Date:  2018-08-29       Impact factor: 5.156

9.  PDGF-BB Promotes Type I IFN-Dependent Vascular Alterations and Monocyte Recruitment in a Model of Dermal Fibrosis.

Authors:  John S Cho; Terry C Fang; Taylor L Reynolds; Daniel J Sofia; Stefan Hamann; Linda C Burkly
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

Review 10.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.